Search results for "Deacetylase inhibitor."

showing 10 items of 73 documents

Changes in histone acetylation in the prefrontal cortex of ethanol-exposed adolescent rats are associated with ethanol-induced place conditioning

2012

Alcohol drinking during adolescence can induce long-lasting effects on the motivation to consume alcohol. Abnormal plasticity in reward-related processes might contribute to the vulnerability of adolescents to drug addiction. We have shown that binge-like ethanol treatment in adolescent rats induces alterations in the dopaminergic system and causes histone modifications in brain reward regions. Considering that histone acetylation regulates transcriptional activity and contributes to drug-induced alterations in gene expression and behavior, we addressed the hypothesis that ethanol is capable of inducing transcriptional changes by histone modifications in specific gene promoters in adolescen…

Malemedicine.medical_specialtyPrefrontal CortexHDAC inhibitionChromatin remodelingHistonesCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineConditioning PsychologicalmedicineAnimalsEpigeneticsRats WistarConditioned place aversionPharmacologyEthanolbiologyHistone modificationsAge FactorsAcetylationSodium butyrateRatsAdolescenceHistone Deacetylase InhibitorsHistoneEndocrinologychemistryBiochemistryAcetylationbiology.proteinBrain stimulation rewardBinge-like ethanol treatmentHistone deacetylaseFOSBNeuropharmacology
researchProduct

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

2014

Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2\ud inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been\ud merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is\ud provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well\ud as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-\ud N8-hydroxyoctanediamide 6.

PharmacologyHistone deacetylase 5medicine.drug_classKinaseHistone deacetylase 2Organic ChemistryHistone deacetylase inhibitorQPharmaceutical ScienceBiologyBiochemistryHDACiVEGFRiHybrids.BiochemistryDocking (molecular)In vivoDrug DiscoverymedicineMolecular MedicineHistone deacetylaseSettore BIO/06 - Anatomia Comparata E CitologiaSemaxanibmedicine.drug
researchProduct

Role of Redox Signaling, Protein Phosphatases and Histone Acetylation in the Inflammatory Cascade in Acute Pancreatitis: Therapeutic Implications

2010

Acute pancreatitis starts as a local inflammation of the pancreatic tissue but often leads to the systemic inflammatory response syndrome and death by multiple organ failure. Pro-inflammatory cytokines, particularly TNF-alpha and Il-1beta, play a pivotal role together with oxidative stress and glutathione depletion in the inflammatory response in this disease. Most inflammatory mediators act through mitogen activated protein kinases and nuclear factor kB. Nevertheless, elucidation of the precise mechanisms involved in activation and attenuation phases of the inflammatory cascade is still underway. Redox signaling mediated by inactivation of protein phosphatases and histone acetylation trigg…

Phosphodiesterase InhibitorsImmunologyPhosphataseBiologyHistonesDual-specificity phosphatasePhosphoprotein PhosphatasesHumansImmunology and AllergyPancreasHistone AcetyltransferasesInflammationPharmacologyHistone AcetyltransferasesKinaseAcetylationGeneral MedicineProtein phosphatase 2ChromatinCell biologyHistone Deacetylase InhibitorsHistonePancreatitisBiochemistryAcetylationAcute Diseasebiology.proteinSignal transductionOxidation-ReductionSignal TransductionInflammation & Allergy - Drug Targets
researchProduct

Image-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors

2014

Recent studies have revealed that several histone deacetylase (HDAC) inhibitors, which are used to study/treat brain diseases, show low blood-brain barrier (BBB) penetration. In addition to low HDAC potency and selectivity observed, poor brain penetrance may account for the high doses needed to achieve therapeutic efficacy. Here we report the development and evaluation of highly potent and blood-brain barrier permeable HDAC inhibitors for CNS applications based on an image-guided approach involving the parallel synthesis and radiolabeling of a series of compounds based on the benzamide HDAC inhibitor, MS-275 as a template. BBB penetration was optimized by rapid carbon-11 labeling and PET im…

PhysiologyCognitive NeuroscienceHistone Deacetylase 2Vascular permeabilityHistone Deacetylase 1Blood–brain barrierBiochemistrylaw.inventionCapillary Permeabilitychemistry.chemical_compoundlawmedicineAnimalsHumansCarbon RadioisotopesBenzamideHistone deacetylase 2BrainCell BiologyGeneral MedicinePenetration (firestop)Papio anubisHDAC1Recombinant ProteinsHistone Deacetylase Inhibitorsmedicine.anatomical_structurechemistryBiochemistryBlood-Brain BarrierPositron-Emission TomographyBenzamidesRecombinant DNABiophysicsDrug EvaluationFemaleHistone deacetylaseRadiopharmaceuticals
researchProduct

The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells

2015

The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer (TNBC) cell line, but its effectiveness was scarce when employed at low doses. This represents an obstacle for a therapeutic utilization of PN. In order to overcome this difficulty we associated to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor. Our results show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN. It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity…

Physiologymedicine.drug_classClinical BiochemistryHistone deacetylase inhibitorCaspase 3Cell Biologychemistry.chemical_compoundchemistryBiochemistryApoptosismedicineCancer researchCytotoxic T cellParthenolideVorinostatProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drugJournal of Cellular Physiology
researchProduct

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.

2019

Abstract Therapeutic options for cutaneous T-cell lymphoma (CTCL) are limited and curative treatment regimens are not available. Thus, new targeted and well-tolerated therapeutic approaches are urgently needed. In this respect, we have recently shown that dimethyl fumerate (DMF) inhibits NF-κB acting as a survival factor in CTCL. Similarly, inhibition of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) has been shown to induce cell death in CTCL especially when combined with histone deacetylase inhibitors. Therefore, we hypothesized that inhibition of Bcl-2 should potentiate NF-κB inhibition in a novel combination treatment of CTCL. We show that, in vitro, the Bcl-2 inhibitors ABT-199 an…

Programmed cell deathT cellImmunologyAntineoplastic AgentsApoptosisBiochemistryMicehemic and lymphatic diseasesCell Line TumormedicineAnimalsHumansRNA Small InterferingCell ProliferationNeoplasm StagingCell DeathDose-Response Relationship Drugbusiness.industryCutaneous T-cell lymphomaNF-kappa BDrug SynergismCell BiologyHematologymedicine.diseaseXenograft Model Antitumor AssaysLymphomaLymphoma T-Cell CutaneousHistone Deacetylase InhibitorsDisease Models Animalmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureCancer researchRNA InterferenceHistone deacetylaseSignal transductionbusinessProtein BindingBlood
researchProduct

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELI…

2013

8507 Background: Therapies approved in US for R/R PTCL have overall response rates (ORR) of 25%-27%. The need for new therapies persists. BELIEF is a pivotal, single-arm study of belinostat in patients with R/R PTCL after failure of ≥1 prior systemic therapies. Methods: Entry criteria were measurable PTCL, platelets ≥ 50,000/µL, no prior HDACi therapy, and adequate organ function. PTCL was confirmed by central pathology review (CPRG). Belinostat 30 min IV infusion at 1000 mg/m2was administered on days 1–5 of a 3 week cycle until progression or unacceptable toxicity. Tumor response was assessed by Cheson 2007 criteria. The primary endpoint was ORR. Results: Patients with R/R PTCL (N=129, 53…

Refractory Peripheral T-cell LymphomaCancer Researchmedicine.drug_classbusiness.industryHistone deacetylase inhibitorchemistry.chemical_compoundOverall response rateOncologychemistryImmunologymedicineCancer researchbusinessBelinostatJournal of Clinical Oncology
researchProduct

The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells

2014

Abstract: The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer (TNBC) cell line, but its effectiveness was scarce when employed at low doses. This represents an obstacle for a therapeutic utilization of PN. In order to overcome this difficulty we associated to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor. Our results show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN. It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagi…

SesquiterpenePhysiologyClinical BiochemistryDown-RegulationApoptosisBreast NeoplasmsApoptosis; Autophagy; Breast Neoplasms; Cell Line Tumor; Down-Regulation; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Sesquiterpenes; Clinical Biochemistry; Cell Biology; Physiology; Medicine (all)Hydroxamic AcidsHydroxamic AcidSettore BIO/10 - BiochimicaCell Line TumorHistone Deacetylase InhibitorAutophagyHumansBiologyVorinostatMedicine (all)NF-kappa BApoptosiDrug SynergismCell BiologyHistone Deacetylase InhibitorsFemaleHuman medicineSesquiterpenesBreast NeoplasmHumanJournal of cellular physiology
researchProduct

The effect of the HDACi JAHA on DNA methylation of breast cancer cells by down-regulating DNMT1 through ERK signaling

2014

Settore BIO/06 - Anatomia Comparata E Citologiahistone deacetylase inhibitor breast cancer cells DNMT1 ERK
researchProduct

Epigenetic agents as an adjunct to active chemotherapy in hematological tumor cell lines

2012

Epigenetic therapy is a new promising area in cancer research that is based on the use of a series of molecules capable of affecting tumor cell growth, differentiation and death by modifying the cellular mechanisms underlying the control of gene expression. Significant enhancement of traditional anticancer drug effects has been also reported by several authors. Our recent research focused on the identification of new epigenetic agent-containing drug combinations to be employed in the therapy of leukemia. The results showed that the new combination of an histone deacetylase (HDAC) inhibitor and the ribonucleotide reductase (RR) inhibitor 3’-methyl-adenosine (3’-Me-Ado) is endowed with a sign…

Settore BIO/14 - Farmacologiaepigenetics leukemia histone deacetylase inhibitors ribonucleotide reductase inhibitors bifunctional agents
researchProduct